Evidence map›Paper›PMID 20551832›Full record

Trial reportJournal of immunotherapy (Hagerstown, Md. : 1997)

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Jordan T Becker, Brian M Olson, Laura E Johnson, James G Davies, Edward J Dunphy, Douglas G McNeel

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Cancer biotherapy: review and prospect.Clinical and experimental medicine · 2024
    Review
  14. Vaccines as treatments for prostate cancer.Nature reviews. Urology · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jordan T BeckerDepartment of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53705, USA.
Brian M Olson
Laura E Johnson
James G Davies
Edward J Dunphy
Douglas G McNeel
University of Wisconsin Carbone Cancer Center · US

Funding

INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid PaseK23RR016489 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MCNEEL, DOUGLAS G · 2002 to 2006
$709k
NCRR NIH HHS 1UL1RR025011NCRR NIH HHS K23 RR016489NCRR NIH HHS K23 RR16489NCRR NIH HHS UL1 RR025011
6 · The paper itself

Abstract

Prostatic acid phosphatase (PAP) is a tumor antigen in prostate cancer and the target of several anti-tumor vaccines in earlier clinical trials. Ultimately, the goal of anti-tumor vaccines is to elicit a sustainable immune response, able to eradicate a tumor, or at least restrain its growth. We have investigated plasmid DNA vaccines and have previously conducted a phase 1 trial in which patients with recurrent prostate cancer were vaccinated with a DNA vaccine encoding PAP. In this study, we investigated the immunologic efficacy of subsequent booster immunizations, and conducted more detailed longitudinal immune analysis, to answer several questions aimed at guiding optimal schedules of vaccine administration for future clinical trials. We report that antigen-specific cytolytic T-cell responses were amplified after immunization in 7 of 12 human leukocyte antigen-A2-expressing individuals, and that multiple immunizations seemed necessary to elicit PAP-specific interferon-gamma-secreting immune responses detectable by enzyme-linked immunosorbent spot assay. Moreover, among individuals who experienced a >/=200% increase in prostate-specific antigen doubling time, long-term PAP-specific interferon-gamma-secreting T-cell responses were detectable in 6 of 8, but in only 1 of 14 individuals without an observed change in prostate-specific antigen doubling time (P=0.001). Finally, we identified that immune responses elicited could be further amplified by subsequent booster immunizations. These results suggest that future trials using this DNA vaccine, and potentially other anti-tumor DNA vaccines, could investigate ongoing schedules of administration with periodic booster immunizations. Moreover, these results suggest that DNA vaccines targeting PAP could potentially be combined in heterologous immunization strategies with other vaccines to further augment PAP-specific T-cell immunity.

Indexed as

Cancer VaccinesAcid PhosphataseAntigens, NeoplasmCell ProliferationCells, CulturedHLA-A2 AntigenHumansImmunization, SecondaryInterferon-gammaLymphocyte ActivationMaleNeoplasm Recurrence, LocalProstatic NeoplasmsProtein Tyrosine PhosphatasesT-Lymphocytes, CytotoxicVaccines, DNAAcid PhosphataseAntigens, NeoplasmCancer VaccinesHLA-A2 AntigenInterferon-gammaprostatic acid phosphataseProtein Tyrosine PhosphatasesVaccines, DNA

Identifiers

PMID20551832
PMCPMC3045767
OpenAlexW2071124717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.